^
    Back
    Association details:
    Biomarker:CD22 positive
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor) +
    Besponsa (inotuzumab ozogamicin) (DNA replication inhibitor, CD22-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    Excerpt:
    ...- CD22-positive disease defined as CD22 expression by >= 20% of lymphoblasts by local hematopathology evaluation....
    Trial ID:
    A041703
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2023
    Title:

    CHEMOTHERAPY-FREE TREATMENT WITH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB FOR OLDER ADULTS WITH NEWLY-DIAGNOSED, PH-NEGATIVE, CD22-POSITIVE, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: ALLIANCE A041703

    Published date:
    05/11/2023
    Excerpt:
    The cumulative CR rates through Induction IA/B/C and Course II were 85% and 97%, respectively...The 1-yr OS was 84% (95% CI 72-98%....InO induction then blinatumomab consolidation is highly active, tolerable therapy for ND, Ph-, CD22+ B-lineage ALL with durable remissions in the majority of pts.